Literature DB >> 7075935

Effect of bombesin on lower esophageal sphincter pressure in humans.

E Corazziari, G Delle Fave, C Pozzessere, A Kohn, L de Magistris, F Anzini, A Torsoli.   

Abstract

Intravenous infusion of bombesin in humans results in increased serum gastrin levels and increased lower esophageal sphincter pressure. To differentiate a gastrin- from a nongastrin-mediated mechanism, the effect of intravenous bombesin infusion on lower esophageal sphincter pressure was studied in 5 healthy subjects and in 5 antrectomized patients. Lower esophageal sphincter pressure was recorded by three continuously perfused catheters with side-openings located 5 mm apart. Blood samples were taken at regular intervals during the study periods to assay gastrin and pancreatic polypeptide. Manometric tracings and blood samples were coded and evaluated blindly. Lower esophageal sphincter pressure increased during bombesin infusion both in normal and antrectomized subjects. The increase had a delayed onset and persisted after discontinuation of bombesin. No correlation was found between lower esophageal sphincter pressure and serum gastrin or pancreatic polypeptide values. These data indicate that the effect of bombesin on lower esophageal sphincter pressure is not gastrin or pancreatic polypeptide mediated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7075935

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  3 in total

1.  Beta adrenergic receptor blockade of feline myocardium. Cardiac mechanics, energetics, and beta adrenoceptor regulation.

Authors:  G Cooper; R L Kent; P McGonigle; A M Watanabe
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

2.  A bombesin immunoreactive peptide in milk.

Authors:  G D Jahnke; L H Lazarus
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

3.  Interactions of bombesin and substance P at the feline lower esophageal sphincter.

Authors:  J C Reynolds; M R Dukehart; A Ouyang; S Cohen
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.